Arceo-Mendoza Rod Marianne, Camacho Pauline
Department of Endocrinology, Osteoporosis & Metabolic Bone Disease Center, Loyola University Medical Center, 2160 South 1st Avenue, Maywood, IL 60153, USA.
Womens Health (Lond). 2015 Jul;11(4):477-82; quiz 483-4. doi: 10.2217/whe.15.14. Epub 2015 Aug 3.
Osteoporosis, a well-defined and growing public health problem, is a disease characterized by increased bone turnover and decreased bone mass with associated skeletal fragility, resulting in an increased risk of fracture. It is often unrecognized until the late stages when fragility fractures have occurred. In adults, early recognition of the disease prior to the occurrence of fractures followed by timely and efficient initiation of appropriate treatment can reduce fracture risk. In this article, we review clinical modalities available to effectively predict fracture risk in patients with osteoporosis. Bone mineral density and presence of clinical risk factors may be combined to provide a more comprehensive osteoporotic fracture risk assessment. Use of FRAX may serve as a general guideline for clinical management and deciding a threshold for cost-effective pharmacological intervention. Elevated bone turnover markers are predictive of high fracture risk and can provide additional clinical information as well.
骨质疏松症是一个明确且日益严重的公共卫生问题,是一种以骨转换增加、骨量减少以及骨骼脆性增加为特征的疾病,会导致骨折风险升高。在脆性骨折发生的晚期阶段之前,该病往往未被识别。在成年人中,在骨折发生之前尽早识别该病,随后及时、有效地启动适当治疗,可降低骨折风险。在本文中,我们综述了可有效预测骨质疏松症患者骨折风险的临床方法。骨密度和临床风险因素的存在情况可相结合,以提供更全面的骨质疏松性骨折风险评估。使用FRAX可作为临床管理以及确定具有成本效益的药物干预阈值的一般指导原则。骨转换标志物升高可预测高骨折风险,并且也能提供额外的临床信息。